If you've spent any time online, you've seen the headlines: “GLP-1s will melt your muscle,” “you'll be on them for the rest of your life,” “stop taking them and every pound comes right back.”  

Most of that is just noise. In this article, we’ll walk through the most common claims about GLP-1 medications — semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) — and hold each one up against what the clinical evidence shows.

GLP-1 myths vs. facts at a glance

Myth: GLP-1s are just for people who want to lose a few vanity pounds

Fact: GLP-1s are weight loss medications used to treat overweight and obesity as the chronic condition it is. Some GLP-1s are also approved for specific related conditions beyond weight alone, like cardiovascular risk reduction or sleep apnea.

FDA labeling limits obesity management medications to patients with a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol. Clinicians aren't prescribing these medications so patients can drop five pounds before an event — they're treating obesity as the chronic disease it is.

This myth tends to persist because of how visible GLP-1s have become in pop culture. Awards season has become something of a running joke about the trend. Hosts like Jimmy Kimmel have opened the Oscars with monologues poking fun at how many stars might be using Ozempic or Wegovy for a slimmer red-carpet look.  

The joke landed hard enough that Eli Lilly, the maker of Zepbound® and Mounjaro®, ran an ad campaign directly addressing it, pointing out that these medications weren't developed so people could fit into a smaller dress or tux for a big night, but for people whose health is affected by obesity.

That health impact goes beyond the number on the scale, too. Some GLP-1s also carry additional, separate FDA approvals tied to specific conditions. For example, Wegovy® is approved to reduce the risk of major cardiovascular events in adults with obesity or overweight and established heart disease, and Zepbound® is approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. These are distinct indications from the weight management approval, so eligibility isn't always just about meeting a BMI threshold.

Myth: Ozempic is FDA-approved for weight loss

Fact: Ozempic and Wegovy are not interchangeable in their approvals, even though both contain semaglutide.  

Ozempic is FDA-approved to treat type 2 diabetes. Wegovy is the semaglutide brand FDA-approved specifically for chronic weight management. When patients use Ozempic for weight loss, it's considered an off-label use. "Off-label use" means prescribing a medication for a purpose, dose, patient population, or condition that hasn't received FDA approval. This is legal and common, but it typically isn't covered by insurance, since insurance coverage is generally tied to a medication's FDA-approved indication.

The mix-up of Ozempic’s use for weight management is one of the most common points of confusion in GLP-1 searches, largely because the two drugs share an active ingredient but not a label.

Myth: You have to take GLP-1s forever, no exceptions

Fact: Treatment length is individualized, but GLP-1s are usually a long-term-therapy conversation for most patients.  

Because obesity is a chronic, relapsing disease, many people need ongoing treatment the same way someone with hypertension needs ongoing blood pressure medication. This is supported by the STEP 1 trial extension, which found that patients who stopped semaglutide after 68 weeks of treatment regained roughly two-thirds of their lost weight within a year — reinforcing that these medications are generally treating an ongoing condition, not a short-term problem.

That said, "forever" isn't automatic for everyone. Some patients, especially those who make substantial, sustained changes to nutrition and activity during treatment, are able to reduce their dose or eventually stop with support from their care team. Real-world data from Epic Research, tracking over 188,000 patients, found that more than half either maintained their weight or continued losing weight after stopping their GLP-1, a more optimistic picture than clinical trial data alone suggests.  

Any decision about stopping a medication should always be made with a clinician, based on your individual health picture. If you’re interested in weight management, book a visit with a knownwell clinician.

Myth: GLP-1s damage your stomach

Fact: GLP-1s slow digestion by design, and while serious stomach damage is rare, side effects like nausea, constipation, and diarrhea, are more common.

The nausea, constipation, and diarrhea associated with GLP-1s come from delayed gastric emptying — a well-documented mechanism of the drug class, not an injury to the stomach lining, according to a 2024 clinical review.

These symptoms are most common when starting treatment or increasing a dose, and they tend to ease over the following weeks. A 2021 clinical practice review on managing GLP-1 side effects found that gradual, individualized dose escalation is the standard first-line strategy for improving tolerability. For most patients, slow dose titration and simple eating adjustments like smaller meals and less fried or spicy food meaningfully reduce discomfort.

For a full breakdown of what to expect and when to call your care team, see knownwell's guide to GLP-1 side effects.

Myth: Muscle loss on GLP-1s isn't a real concern

Fact: Muscle loss is a real, well-documented effect, but it's mediated by how someone loses weight, not caused directly by the medication itself.

Muscle loss happens any time the body loses a significant amount of weight, regardless of the method. When researchers scanned patients in two major GLP-1 trials to see exactly what kind of weight they were losing — fat versus muscle — the results varied by medication. In the semaglutide trial (Wegovy), about 40% of the weight patients lost came from muscle, with the rest from fat. In the tirzepatide trial (Zepbound), muscle made up closer to a quarter of the weight lost, about the same split seen with diet-and-exercise-only weight loss in the same study.

That difference points to what's actually driving the muscle loss: it's tied to how much someone eats, how active they are, and how quickly the weight comes off — not something the drug is doing to muscle tissue directly. The same physiology applies whether the weight loss comes from a GLP-1, calorie restriction, or bariatric surgery. This is also why the two things most consistently shown to preserve muscle work by directly addressing those mediating factors: eating enough protein counteracts the calorie deficit's pull on muscle tissue, and resistance training gives the body a reason to hold onto the muscle it has.  

This is exactly why knownwell pairs every GLP-1 prescription with support from a registered dietitian and a health coach, so protein and strength training are built into the plan from day one rather than an afterthought. Get started with knownwell.  

Myth: "Ozempic face" means the drug is uniquely harmful

Fact: This is a side effect of rapid weight loss in general, not something specific to Ozempic or GLP-1s as a medication class.  

"Ozempic face" describes the hollowed, sunken look that can appear when someone loses facial fat and muscle quickly. It happens because facial fat pads provide youthful volume, and skin doesn't always retract as quickly as fat disappears. The same phenomenon can happen after bariatric surgery or any fast, significant weight loss.

The research backs this up: a systematic review published in a plastic surgery journal examined the evidence behind "Ozempic face" and found nothing to suggest GLP-1 medications cause facial fat loss any differently than other rapid weight loss does — the researchers noted the term was popularized by media coverage rather than by any new clinical finding.  

A separate review in the Journal of Drugs in Dermatology compared soft-tissue outcomes across bariatric surgery, diet-based weight loss, and GLP-1 therapy, and found broadly similar effects on skin laxity and facial volume across all three, the rate and amount of weight lost mattered far more than the method used to lose it.

The main levers for managing it are the same ones that help with muscle preservation more broadly: slower dose escalation, adequate protein, hydration, and strength training. While it's a cosmetic tradeoff worth discussing with your clinician, it is not evidence that Ozempic, or GLP-1s, are unsafe.

Myth: Natural or "GLP-1 boosting" supplements work just as well

Fact: Natural or "GLP-1 boosting" supplements are not a smaller or cheaper version of the FDA-approved GLP-1s. They are an unregulated category of supplement with real, documented harm.

There are two things circulating under this "natural GLP-1" umbrella, and both deserve to be addressed.

Over-the-counter "GLP-1 booster" supplements like gummies, powders, and pills sold under names invoking GLP-1, often containing berberine, chromium, or fiber blends, are dietary supplements, not drugs.  

Under U.S. law, that means the manufacturer doesn't have to prove the product works, doesn't have to prove it's safe, and doesn't need FDA approval before selling it. The FDA maintains an active list of weight loss products found to contain hidden drug ingredients, warning that these products are often falsely marketed as "natural" or as dietary supplements while posing serious health risks, including hospitalization.  

Supplement makers marketing products as GLP-1 alternatives are currently facing consumer lawsuits alleging deceptive advertising, including claims that products were marketed as natural substitutes for prescription GLP-1 drugs without evidence to support that claim.

"Natural semaglutide" or unregulated injectable products sold at med spas are a different, arguably more dangerous problem. The FDA has issued direct warnings about fraudulent and counterfeit products sold under these labels. In one documented case, the FDA found non-sterile drug conditions at a facility supplying these products, creating risk of life-threatening infections. As of early 2025, the FDA had received more than 455 adverse event reports tied to compounded semaglutide and over 320 tied to compounded tirzepatide — including hospitalizations from dosing errors, and reports of contamination.

This is exactly why knownwell only prescribes FDA-approved obesity management medications. If cost or access is the reason you're considering an alternative, that's a real and valid concern, but the answer is a conversation with your clinician about manufacturer savings programs, insurance navigation, or a different FDA-approved medication.

Our recent article on authentic vs. compounded GLP-1 medications walks through what changed after the FDA ended the semaglutide shortage designation and what your options are now.

Myth: Everyone loses the same amount of weight on a GLP-1

Fact: Individual response to GLP-1s varies substantially.  

It's easy to see why this myth persists. Headlines and social media tend to boil GLP-1 results down to a single number, like "15% weight loss" or "20% weight loss," as if that's what everyone can expect. But that number is an average across thousands of trial participants. The clinical trial data itself, when you look past the averages, actually shows just how much individual results can differ.

The commonly cited headline numbers come from the two flagship trials: STEP 1 found semaglutide produced average weight loss of about 15%, and SURMOUNT-1 found tirzepatide produced average losses of 15–21% depending on dose. But an average hides a wide range of individual outcomes. In SURMOUNT-1, roughly 85–91% of patients lost at least 5% of their body weight, depending on dose — meaning somewhere between 1 in 10 and 1 in 6 patients didn't reach even that threshold. At the higher end, 57% of patients on the top tirzepatide dose lost 20% or more, while others lost far less.

Semaglutide shows the same pattern. Across the STEP trials, research reviewing patient variability found that people with type 2 diabetes lost meaningfully less on semaglutide (about 9.6% on average) than people without diabetes (about 14.9%). Genetics appear to matter, too. Some patients have what researchers call a "hungry gut" phenotype, tied to faster gastric emptying and lower natural satiety, which is associated with a stronger response to GLP-1 therapy. Sex, starting weight, and consistency with the medication all shape outcomes as well.

This is exactly why knownwell's care model pairs medication with personalized nutrition counseling and health coaching, rather than treating a prescription as the whole plan.

Myth: Insurance always covers GLP-1s

Fact: Coverage has actually been getting harder to count on, even for patients who medically qualify. That doesn't mean you're on your own to figure it out.

A large share of Americans with insurance are now in plans that exclude coverage for obesity medications entirely or cover only a single option. Medicare coverage has shifted too, though not only in the difficult direction: the Medicare GLP-1 Bridge program officially went live on July 1, 2026, giving eligible beneficiaries access to select GLP-1 medications for a flat $50 monthly copay through the end of 2027.

The good news is that a lot of coverage denials aren't the end of the road, either. knownwell has a dedicated prior authorization team to navigate the heavy lifting: gathering the clinical documentation insurers require, submitting and tracking prior authorizations, and re-filing or appealing when a claim is denied.  

If your coverage has changed or you're navigating a prior authorization, knownwell has dedicated guides on insurance barriers for GLP-1 medications, losing GLP-1 coverage, and prior authorization under the Medicare GLP-1 Bridge.

Myth: Using medication for weight loss is "cheating"

Fact: This framing blames people for something that isn't within their control to begin with and it’s not medically accurate.

Body weight is one of the most heritable human traits there is. Twin and family studies consistently put the heritability of body weight and BMI at 40–70%, in the same range as traits like height, which nobody frames as a matter of discipline. Genes shape how the body regulates hunger, stores fat, and signals fullness through hormones like leptin and ghrelin. Layer in environment, metabolism, sleep, stress, and hormonal shifts across a lifetime, and it becomes clear that body weight was never simply a reflection on effort or willpower.

That's exactly why obesity is classified as a chronic disease, not a personal failing. Treating overweight and obesity with medication is no different from treating high blood pressure or type 2 diabetes with medication alongside lifestyle changes. No one tells someone managing hypertension that their prescription is "cheating" to have normal blood pressure.  

If you're navigating judgment about using a GLP-1, that reaction says more about lingering cultural bias around weight than it does about your choices. knownwell's care model exists precisely because everyone deserves compassionate, evidence-based care. If you’re interested in starting weight management, book a visit with a knownwell clinician.

Myth: Compounded and prescription GLP-1s are basically the same

Fact: only FDA-approved GLP-1s go through the FDA's review of safety, purity, and manufacturing quality — and the FDA has been moving decisively to close the door on compounded versions entirely.

Compounded semaglutide and tirzepatide became widely available starting in 2022, when surging demand created genuine shortages of Ozempic, Wegovy, and later Mounjaro and Zepbound. Under federal law, that shortage status is what temporarily allowed compounding pharmacies to legally produce copies of these medications. That exception no longer applies: the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025.

In April 2026, the agency went a step further and formally proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list of substances outsourcing facilities are allowed to compound in bulk, finding no clinical need for compounded versions to exist at all now that FDA-approved options are widely available. The FDA extended the public comment period on this proposal to July 30, 2026, and a final decision hasn't been issued yet. If finalized, this would close the primary legal pathway that has let GLP-1 compounders mass-produce these medications, even outside of a shortage — though liraglutide, unlike the other two, remains on the FDA's active shortage list for now, so it can still legally be compounded in the meantime.

Compounded drugs, by definition, skip the premarket review the FDA requires of approved medications. They go through no evaluation of manufacturing quality, no inspection of the facility, no independent confirmation that the product is what the label says it is. As the FDA's own shortage-resolution order put it, compounded drugs "have not undergone FDA premarket review for safety, effectiveness, and quality, and lack a premarket inspection and finding of manufacturing quality" the way approved drugs do.

knownwell helps patients transition to authentic, FDA-approved medications through manufacturer savings programs and insurance, with support that's always compassionate and non-judgmental. Learn more about weight loss medication pricing.

GLP-1s are one of the most effective tools available for treating obesity, and they're also one of the most misunderstood, partly because so much of what circulates online is either oversimplified or overstated in the opposite direction.  

Almost every myth above is some version of "it's real, but it's manageable" or "it's not as absolute as it sounds." That's exactly why ongoing clinical support matters: a knownwell clinician, registered dietitian, andhealth coach can help you separate what's true for GLP-1s in general from what's actually happening in your body.

If you're considering a GLP-1, currently taking one, or trying to figure out your next step after a coverage change, book a visit with a knownwell clinician to build a plan around your goals, your health history, and your budget.

Frequently asked questions

Can you microdose a GLP-1 for extra benefits?  

There's no clinical evidence supporting microdosing below FDA-approved starting doses — no standardized protocol, no long-term safety data. Many people who describe themselves as "microdosing" are actually on a recognized FDA-approved starter dose. Read the full breakdown in Microdosing GLP-1s: What Medical Research Actually Says.

Can you take a GLP-1 while breastfeeding?  

Generally it’s not recommended, though it's an individualized decision to make with your clinician. Most guidance suggests waiting until breastfeeding ends. See Can You Take GLP-1s While Breastfeeding: Current Evidence for what the data shows.

Do GLP-1s cause blindness?  

No, this is an exaggeration. Some research has identified a possible link between semaglutide and a rare optic nerve condition called NAION, and regulators have added related warnings. It's not evidence that GLP-1s cause blindness broadly. Anyone on a GLP-1 who notices sudden vision changes should seek care immediately.

Are GLP-1 pills as effective as injections?  

Clinical trial data show comparable results across GLP-1 pills and injections.

In the ATTAIN-1 trial, participants taking Foundayo (orforglipron) lost an average 12.4% of their starting body weight. Similarly, in the OASIS 4 trial, participants taking the Wegovy pill (oral semaglutide) lost an average of 13.6% of their starting body weight.

For more detail, see our guide to GLP-1 pills.

Sources

• "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight." Diabetes, Obesity and Metabolism, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/

• "Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide." Journal of Clinical Endocrinology & Metabolism. https://academic.oup.com/jcem/article/110/1/1/7824836

• Davies, M., Færch, L., et al. "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial." Lancet, 2021. https://pubmed.ncbi.nlm.nih.gov/33667417/

• Eli Lilly and Company. "Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care." https://investor.lilly.com/news-releases/news-release-details/lillys-newest-phase-get-better-campaign-challenges

• Epic Research. "Two Years After Stopping GLP-1s, Most Patients Sustain at Least Some Weight Loss." 2025. https://www.epicresearch.org/articles/two-years-after-stopping-glp-1s-most-patients-sustain-at-least-some-weight-loss/

• "FDA Moves to Permanently Close the Door on Compounded GLP-1s." Pharmacy Times. https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s

• Food and Drug Administration. Declaratory Order: Resolution of Shortage of Semaglutide Injection Products (February 21, 2025). https://www.fda.gov/media/185526/download

• Food and Drug Administration. "Avoiding Products Contaminated with Hidden Ingredients." https://www.fda.gov/drugs/medication-health-fraud/avoiding-products-contaminated-hidden-ingredients

• Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (April 30, 2026). https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

• Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

• Food and Drug Administration. "Weight Loss Product Notifications." https://www.fda.gov/drugs/medication-health-fraud-notifications/weight-loss-product-notifications

• "Genetic and Syndromic Causes of Obesity: Diagnosis and Management." StatPearls, NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK573068/

• Jastreboff, A.M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

• "JDD Buzz | Impact of Weight Loss on Soft Tissue." https://nextstepsinderm.com/jdd-corner/jdd-buzz-series/ozempic-face-dermatology-treatment/

• Knop, F.K., et al. "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity" (OASIS 1). The Lancet, 2023. https://pubmed.ncbi.nlm.nih.gov/37385278/

• Lilly's official SURMOUNT-1 results release. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine

• "Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice." 2021. https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616

• "'Ozempic Face' in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions." https://pmc.ncbi.nlm.nih.gov/articles/PMC12232544/

• "Semaglutide Safety Alerts, Recalls & Warnings." Drugs.com. https://www.drugs.com/fda-alerts/3878-0.html

• "Unverified GLP-1-Related Claims Flood Food, Supplement Markets." Bloomberg Law. https://news.bloomberglaw.com/health-law-and-business/unverified-glp-1-related-claims-flood-food-supplement-markets

• "What's behind the variable responses to semaglutide for weight loss?" Summit Rx Pharmacy. https://www.summitrxpharmacy.com/post/what-s-behind-the-variable-responses-to-semaglutide-for-weight-loss

• Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

• Wilding, J.P.H., et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism, 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/